Health News Releases

July 30, 11:30

Takeda Reports Strong First Quarter FY2023 Results, Driven by Growth & Launch Products

Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for the first quarter of fiscal year 2023 (period ended June 30, 2023). Takeda chief financial officer, Costa Saroukos, comment

July 28, 09:25

Medisca Expands Strategic Partnerships to Drive Patient Access to Critical Medications

Medisca has announced the expansion of a network of strategic partnerships aimed at securing and stabilizing worldwide access to high quality active pharmaceutical ingredients (APIs) for the preparati

July 27, 14:16

Galderma Achieves Record 2 B USD Net Sales for a Six-Month Period in H1 2023, as It Continues to Demonstrate Leading Execution and Innovation Capabilities in Dermatology

Galderma: · Galderma maintained strong momentum across all product categories reaching 2,003 M USD net sales in H1 2023, up 6.9% year-on-year on a constant currency basis · Growth primarily driven

July 27, 10:35

The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1

Takeda (TSE:4502/NYSE:TAK) today announced that data from the Phase 2 study of orexin receptor 2 (OX2R) agonist TAK-994 in patients with narcolepsy type 1 (NT1) was published in The New England Journa

July 27, 10:00

AmbioPharm, a Global Peptide CDMO

AmbioPharm, a worldwide leader in peptide API CDMO services, continues growth to meet capacity demands for late phase and commercial peptide production. A reliable peptide CDMO with manufacturing faci

July 26, 17:35

Aleph Farms Submits First Ever Application for Cultivated Meat in Europe

Aleph Farms, a cellular agriculture company that enhances sustainability, food security and animal welfare in our food systems, today announced that it has submitted an application for regulatory appr

July 26, 17:15

BaroPace Receives Approval for First-in-Human Clinical Trial

BaroPace, Inc., a medical technology company dedicated to using blood pressure to regulate pacemakers for patients with heart failure with preserved ejection fraction and hypertension, announced today

July 26, 10:45

Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease

The European Commission (EC) approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease (CKD),[8] Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced

July 25, 11:30

Kenvue To File Form S-4 Registration Statement in Connection with Johnson & Johnson Exchange Offer Announcement

Kenvue Inc. (NYSE: KVUE) (“Kenvue”) announced that it intends to file a Form S-4 Registration Statement today with the Securities and Exchange Commission (the “SEC”) in connection with Johnson & Johns

July 25, 11:15

Orthogon Therapeutics Celebrates Major Technical Milestone and Secures Additional $6M Toward a Pioneering Drug for BK Virus

Orthogon Therapeutics LLC, a trailblazer in the field of antiviral therapeutics, today announced a dual victory. Orthogon’s lead molecule has successfully completed acute toxicity studies, marking a p

July 21, 11:45

Kenvue Initiates Quarterly Cash Dividend

Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced that its Board of Directors has declared a dividend payable in the third quarter

July 17, 09:30

TauRx’s Hydromethylthionine Mesylate (HMTM) Demonstrates Significant Reduction in Neurodegeneration in Alzheimer’s Disease (AD)

TauRx Pharmaceuticals Ltd., a global leader in Tau-based research in Alzheimer’s disease (AD), today announced results from a prespecified analysis of the Phase 3 LUCIDITY trial that measured the impa

July 11, 10:05

Wyss Center Appoints Dr. Craig Cook as New Head of Business Development and Licensing

The Wyss Center, a leading non-profit research center dedicated to innovating and accelerating technologies and therapies for neurological and mental health disorders, is pleased to announce the appoi

July 07, 09:10

Biocytogen Pharmaceuticals Enters Into License Agreement With Pheon Therapeutics

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces an antibody license agree

July 06, 13:08

Rimini Support™ Enables Gachon University Gil Medical Center to Advance its Digital Transformation Projects and Continue to Serve the Community as a Trailblazer Hospital

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, products and services, the leading third-party support provider for Oracle and SAP software, and a Sale

July 06, 10:15

First Distribution Agreement Executed with Sonic Healthcare

Microba Life Sciences Limited (ASX: MAP) (“Microba”) is pleased to announce that it has executed a commercial agreement with Sonic Healthcare Limited (ASX: SHL) through a wholly owned subsidiary Dougl

July 05, 09:30

P&G Grooming Invites Dermatologist Community to Go ‘Skin Deep Into Grooming’ at the 25th World Congress of Dermatology

At this year’s 25th World Congress of Dermatology held in Singapore (July 3rd - 8th), P&G’s Grooming Division will spotlight product solutions routed in 120 years of innovation heritage and scientific

July 04, 17:11

Galderma @ WCD 2023: Late-Breaking Phase III Results for Nemolizumab Monotherapy in Prurigo Nodularis Show a Significant Proportion of Itch-Free Patients by Week 4

Galderma presented the latest data from its pivotal phase III OLYMPIA 2 trial at the 25th World Congress of Dermatology (WCD) in Singapore. The results highlight the rapid onset of action of nemolizum

July 04, 16:25

Spesolimab prevents generalized pustular psoriasis flares in EFFISAYIL™ 2 trial

Today, at the 25th World Congress of Dermatology (WCD), Boehringer Ingelheim presented new late-breaking data from the EFFISAYIL™ 2 trial showing that spesolimab significantly reduced the risk of GPP

July 04, 10:10

Experts Call for Protocols to Speed up Referrals for Pulmonary Hypertension to Specialized Centers

The IMPAHCT (International Meeting on Pulmonary Hypertension Clinical Treatment) event, organized by the pharmaceutical company Ferrer, has brought together more than 150 pulmonologists and cardiologi

July 04, 09:50

After the Great Success Achieved in the United States and Canada, DEKA Launches Three Extraordinary Laser and Microwave Platforms at the World Congress of Dermatology in Singapore

DEKA, a subsidiary of the El.En. Group, a company listed on the Eurostar Next of the Italian Stock Exchange (ELN.MI), specialized in the development and manufacturing of cutting-edge Energy Based Devi

June 29, 14:05

Thermo Fisher Scientific Introduces Tumoroid Culture Medium to Accelerate Development of Novel Cancer Therapies

Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the Gibco™ OncoPro™ Tumoroid Culture Medium Kit*, the first commercially available culture medium specifica

June 29, 11:40

AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health

AstraZeneca has announced a $400 million investment in its global AZ Forest programme, raising its commitment to plant 200 million trees by 2030 and ensure their long-term survival. This includes new

June 29, 09:55

Microba Commences Phase I Clinical Trial for IBD Therapeutic

Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) today announces that the first participants have been successfully dosed in the Phase I Clinical Trial of MAP 315, in Microba’s Th

June 29, 09:15

Aktana Announces New CEO

Aktana, the leader in intelligent customer engagement for the global life sciences industry, welcomes John Vitalie as Chief Executive Officer. Before joining Aktana, John led global teams across va

News by Region

News by Industry